Advertisement
Canada markets open in 7 hours 32 minutes
  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CAD/USD

    0.7258
    -0.0006 (-0.08%)
     
  • CRUDE OIL

    84.24
    +1.51 (+1.83%)
     
  • Bitcoin CAD

    85,607.63
    +1,112.53 (+1.32%)
     
  • CMC Crypto 200

    1,283.03
    +397.49 (+43.49%)
     
  • GOLD FUTURES

    2,395.30
    -2.70 (-0.11%)
     
  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     
  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     
  • NASDAQ futures

    17,376.75
    -170.50 (-0.97%)
     
  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • NIKKEI 225

    37,192.88
    -886.82 (-2.33%)
     
  • CAD/EUR

    0.6823
    +0.0002 (+0.03%)
     

A Look at Sage Therapeutics’ NMDA Receptor Portfolio

A Look at Sage Therapeutics’ NMDA Receptor Portfolio

As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.